WinstonWınston
Back
Stock

Sernova

SEOVF
Biotechnology · Healthcare
Price
$0.10
+0.00 (+0.00%)
Market Cap
$37.8M
Exchange
Other OTC
Winston Score
Winston looking sleepy
No score yet — nothing to grade.
This is a pre-revenue company — it has no sales yet, just exploration or development costs. There’s no operating business to grade on profitability, margins or cash flow, so the Winston Score stays blank until it starts booking revenue.

Share count rising — dilution

+33.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 245.5M (2021) → 328.3M (2025)

§Winston Score History

The full picture

Sernova Corp. is a Canadian firm, established in 1998 and headquartered in London, that specializes in advanced regenerative medicine therapeutics and is currently in its clinical development phase. The company's primary objective is to innovate and bring to market novel treatments, with a core focus on its unique "Cell Pouch" system. This sophisticated medical device is engineered to create a highly vascularized environment within the body, enabling the successful implantation and integration of therapeutic cells. Once integrated, these cells are designed to continuously release vital proteins or hormones, providing a long-term approach to managing debilitating chronic conditions like diabetes, hemophilia, and thyroid disease. Accompanying the Cell Pouch are related technologies that involve specialized therapeutic cells and methods to shield them from the body's immune response. Sernova actively collaborates with AgeX Therapeutics, Inc. to develop immune-protected therapeutic cells and maintains a research partnership with the University of Miami to further refine its Cell Pouch cell therapy platform.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+45.2% YoY

YoY Growth Rate

Strong earnings growth

R&D Spend

C$7M/ year

Declining (-68% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Cash Runway

~0 months

C$63,362 cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Sernova has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
N/A
Data not available
Profit after running costs
Operating Margin
N/A
Data not available
Return on the money invested
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
N/A
Data not available
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
8/8 quarters
Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial